Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD79B (CD79b Molecule)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Archer™ VARIANTPlex™ Lymphoma panel

Archer™ VARIANTPlex™ Lymphoma panel

›

CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2
MYD88 L265P + CD79B mutation	Diffuse Large B Cell Lymphoma	MYD88 L265P + CD79B mutation	Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3
CD79B mutation	Lymphoma	CD79B mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 L265P + CD79B mutation	Lymphoma	MYD88 L265P + CD79B mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
MYD88 mutation + CD79B mutation	Lymphoma	MYD88 mutation + CD79B mutation	Lymphoma	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3
CD79B mutation	Lymphoma	CD79B mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D